Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 7/20 | 0.38 |
| ▸ | RXRB | P28702 | 6/20 | 0.38 |
| ▸ | RXRG | P48443 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489112 | 0.95 | BCL2L1 (0.56) | BCL2L1BADTSHRRXRARXRB | |
| SCHEMBL6570394 | 0.93 | BCL2L1 (0.54) | BCL2L1BADTSHRRXRARXRB | |
| SCHEMBL7444249 | 0.85 | — | — | |
| SCHEMBL10494178 | 0.77 | TSHR (0.44) | BCL2L1BADTSHRCYP2A6MAOA | |
| SCHEMBL17698887 | 0.75 | BCL2L1 (0.54) | BCL2L1BADTSHRSIGMAR1NISCH | |
| SCHEMBL29488244 | 0.75 | BCL2L1 (0.54) | BCL2L1BADTSHRSIGMAR1NISCH | |
| SCHEMBL29892288 | 0.73 | BCL2L1 (0.52) | BCL2L1BADTSHRRXRASIGMAR1 | |
| SCHEMBL413550 | 0.73 | BCL2L1 (0.52) | BCL2L1BADTSHRRXRASIGMAR1 | |
| SCHEMBL2778545 | 0.73 | BCL2L1 (0.52) | BCL2L1BADTSHRRXRARXRB | |
| SCHEMBL9505658 | 0.71 | BCL2L1 (0.50) | BCL2L1BADTSHRRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-10973913-B2 | JAK inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| CN-108135175-B | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3355699-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE INC (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE, INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| CN-108135175-A | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2017143014-A1 | JAK INHIBITORS AND USES THEREOF | KIM BRIAN (US) | 2017-08-24 | — | — | WO | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2344157-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2344158-A1 | Use of isoQC inhibitors | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | BCL2L1 4775/4885BAD 4370/4885TSHR 1599/4885 |
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | SUV39H2, SUV39H1, EZH1 | BCL2L1 1148/4885BAD 1102/4885TSHR 4639/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | BCL2L1 4407/4885BAD 4170/4885TSHR 2954/4885 |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | BCL2L1 3198/4885BAD 1176/4885TSHR 3149/4885 |
| US-10973913-B2 | JAK inhibitors and uses thereof | JAK2, JAK1, JAK3 | BCL2L1 3732/4885BAD 1096/4885TSHR 2654/4885 |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | BCL2L1 3108/4885BAD 738/4885TSHR 3107/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | BCL2L1 2635/4885BAD 1708/4885TSHR 4798/4885 |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | BCL2L1 3732/4885BAD 1096/4885TSHR 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.